CP 404Alternative Names: CP-404
Latest Information Update: 28 Apr 2016
At a glance
- Originator Compellis Pharmaceuticals
- Developer Compellis Pharmaceuticals; Pennington Biomedical Research Center
- Class Small molecules
- Mechanism of Action Calcium channel antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 28 Apr 2016 Discontinued - Phase-I for Obesity in USA (Intranasal) (Compellis Pipeline, April 2016)